search button

Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer

  • Authors:
    • Wahid Mdah
    • Raneen Mzalbat
    • Peter Gilbey
    • Moshe Stein
    • Adi Sharabi
    • Jamal Zidan

  • View Affiliations

  • Published online on: July 11, 2014     https://doi.org/10.3892/mco.2014.346
  • Pages: 1107-1110
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human epidermal growth factor receptor 2 (HER-2) is a well recognized prognostic and predictive factor in breast cancer. However, the role of HER-2 in thyroid cancer remains controversial. The aim of this study was to evaluate HER-2 expression in differentiated thyroid cancer (DTC) and determine whether there is an association with other clinical and pathological characteristics. A total of 69 patients with DTC were investigated, 58 of whom had papillary and 11 follicular carcinomas. HER-2 was detected by immunohistochemical examination on sections from formalin‑fixed, paraffin‑embedded tumor tissues. Tumors with HER-2 expression classed as +1 and +2 were retested with chromogenic in situ hybridization. Clinicopathological data were retrieved from the hospital records of the patients. HER-2 overexpression was found in 4 (6.9%) of the 58 patients with papillary carcinoma, whereas there was no HER-2 overexpression in any of the 11 cases of follicular carcinoma. There was no association of HER-2 expression with tumor size, pathological grade and cervical lymph node metastasis. In conclusion, there were no HER-2 positive cases of follicular carcinoma and the incidence of HER-2 overexpression in papillary carcinoma was very low. Thus, HER-2 cannot be used routinely as a prognostic or predictive factor in DTC. The expression of other epidermal growth factor receptors in DTC merits further investigation.
View References

Related Articles

Journal Cover

November-December 2014
Volume 2 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Mdah W, Mzalbat R, Gilbey P, Stein M, Sharabi A and Zidan J: Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer. Mol Clin Oncol 2: 1107-1110, 2014
APA
Mdah, W., Mzalbat, R., Gilbey, P., Stein, M., Sharabi, A., & Zidan, J. (2014). Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer. Molecular and Clinical Oncology, 2, 1107-1110. https://doi.org/10.3892/mco.2014.346
MLA
Mdah, W., Mzalbat, R., Gilbey, P., Stein, M., Sharabi, A., Zidan, J."Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer". Molecular and Clinical Oncology 2.6 (2014): 1107-1110.
Chicago
Mdah, W., Mzalbat, R., Gilbey, P., Stein, M., Sharabi, A., Zidan, J."Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer". Molecular and Clinical Oncology 2, no. 6 (2014): 1107-1110. https://doi.org/10.3892/mco.2014.346